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Abstract
IgE antibodies, administered to mice together with their specific antigen, enhance antibody and CD4
+ T cell responses to
this antigen. The effect is dependent on the low affinity receptor for IgE, CD23, and the receptor must be expressed on B
cells. In vitro, IgE-antigen complexes are endocytosed via CD23 on B cells, which subsequently present the antigen to CD4
+
T cells. This mechanism has been suggested to explain also IgE-mediated enhancement of immune responses in vivo.W e
recently found that CD23
+ B cells capture IgE-antigen complexes in peripheral blood and rapidly transport them to B cell
follicles in the spleen. This provides an alternative explanation for the requirement for CD23
+ B cells. The aim of the present
study was to determine whether B-cell mediated antigen presentation of IgE-antigen complexes explains the enhancing
effect of IgE on immune responses in vivo. The ability of spleen cells, taken from mice 1–4 h after immunization with IgE-
antigen, to present antigen to specific CD4
+ T cells was analyzed. Antigen presentation was intact when spleens were
depleted of CD19
+ cells (i.e., primarily B cells) but was severely impaired after depletion of CD11c
+ cells (i.e., primarily
dendritic cells). In agreement with this, the ability of IgE to enhance proliferation of CD4
+ T cells was abolished in CD11c-
DTR mice conditionally depleted of CD11c
+ cells. Finally, the lack of IgE-mediated enhancemen of CD4
+ T cell responses in
CD23
-/- mice could be rescued by transfer of MHC-II-compatible as well as by MHC-II-incompatible CD23
+ B cells. These
findings argue against the idea that IgE-mediated enhancement of specific CD4
+ T cell responses in vivo is caused by
increased antigen presentation by B cells. A model where CD23
+ B cells act as antigen transporting cells, delivering antigen
to CD11c
+ cells for presentation to T cells is consistent with available experimental data.
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Introduction
Apart from initiating various defense mechanisms via Fc-
receptor binding or complement activation, antibodies have the
capacity to regulate the immune responses against the antigen they
are specific for [1]. This phenomenon is called antibody feedback
regulation and has been known for over a century [2], although
the molecular mechanisms behind are still not completely
understood [1]. The most well known type of antibody feedback
regulation is the ability of IgG to suppress antibody responses
against large particulate antigens such as erythrocytes. This has
been used successfully in the clinic since the 1960’s to prevent
Rhesus negative women from becoming immunized against fetal
Rhesus positive erythrocytes, transferred via transplacental
hemorrhage [3,4]. In other situations, antibodies can enhance
antibody responses. IgG has a dual role and, depending on
subclass, enhances responses to protein antigens via Fc-gamma-
receptors [5] or complement [6]. IgM is another well known
enhancer of antibody responses, which utilizes the complement
system [7,8]. An interesting feedback circuit is the one initiated by
IgE antibodies. TNP (trinitrophenyl)-specific IgE administered
intravenously (i.v.) to mice together with small protein antigens
such as BSA (bovine serum albumin)-TNP or OVA (ovalbumin)-
TNP induce a several 100-fold higher primary antibody response
than does antigen administered alone [9,10,11,12]. The effect is
most pronounced on the IgG response and formation of germinal
centers and recall responses are also enhanced [13,14,15]. The
enhancing effect of IgE on antibody responses is completely
dependent on the presence of CD23, the low affinity receptor for
IgE [9,10,16]. Murine CD23 exists in two isoforms, CD23a and
CD23b. CD23a is constitutively expressed on B cells and follicullar
dendritic cells (FDC), but not on dendritic cells [17,18], and is the
isoform involved in IgE-mediated enhancement of antibody
responses [12]. The CD23b isoform has been found on enterocytes
in the intestine and recently also on lung epithelial cells [19,20]. It
is well established by several independent groups that human as
well as mouse B cells take up IgE-antigen complexes via CD23
and present the antigenic peptides to CD4
+ T cells in vitro
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21760[21,22,23,24,25]. In analogy with these findings, TNP-specific IgE
administered with OVA-TNP to mice enhances proliferation and
activation of OVA-specific CD4
+ T cells in vivo [15,16]. The effect
on T cells as well as on antibody responses requires that CD23 is
expressed on B cells [11,16]. These findings are compatible with
the idea that the enhancing effect of IgE on antibody and T cell
responses in vivo is explained by B cell-mediated antigen
presentation. Whether B cells are able to present antigen to naı ¨ve
T cells or not has been debated, and there is experimental support
both in favour of [26,27,28,29,30] and against [31,32,33,34] this
idea. In a previous study, using the same experimental approach as
in the present one, we followed the transport of IgE-antigen
complexes in vivo [15]. IgE-antigen was found on the majority of
B cells in the blood ten minutes after immunization and were
detected in the splenic follicles on CD23
hiCD21
dim cells (follicular
B cells) after 30 minutes [15]. This observation provided an
alternative explanation for the requirement of CD23
+ B cells,
suggesting that the enhancing effect of IgE on immune responses
could be caused by concentrating the antigen to B cell follicles.
The findings prompted us to ask whether CD23
+ B cells are
required both for transport and presentation of IgE-antigen
complexes or whether they primarily act to transport the antigen.
The results argue against the idea that presentation of IgE-antigen
by CD23
+ B cells is the explanation for IgE-mediated enhance-
ment of CD4
+ T cell responses in vivo.
Materials and Methods
Ethics statement
All animal experiments were approved by Uppsala Animal
Research Ethics Committee (protocol numbers C117/7 and
C146/10). The mice were bred and maintained in the animal
facilities at the National Veterinary Institute (Uppsala, Sweden).
Skilled personnel under the supervision of the veterinarian in
charge routinely observed the health status of the mice.
Mice
C57BL/6 and CD11c-DTR mice were obtained from Jackson
Laboratories (Bar Harbor, ME), BALB/c mice from Bommice
(Ry, Denmark), CD23-deficient (CD23
-/-) mice were a kind gift
from Dr Kishimoto [10] and were backcrossed to BALB/c for 10
generations [16]. DO11.10 mice [35] were obtained from Dr
Westerberg, Karolinska Institute, Stockholm. DO11.10 mice are
BALB/c mice that carry transgenic TCR a and b chains, resulting
in a TCR recognizing OVA323-339 together with MHC class II
I-A
d. CD11c-DTR mice are BALB/c mice transgenic for a high
affinity human diphtheria toxin receptor expressed under the cd11c
promoter [36].
Offspring from heterozygous CD11c-DTR mated with wildtype
BALB/c mice were used and DNA was extracted from the tail tip
by digestion in 40 ml 1x modified Gitschier buffer (67 mM Tris-
HCl (pH 8.8), 0.166 mM (NH4)2SO4, 6.5 mM MgCl2) with 1% 2-
mercaptoethanol and 0.5% Triton X-100 at 95uC for 5 min.
Thereafter, 0.5 mg/ml proteinase K (Qiagen, Hilden, Germany)
was added and the digesting tissue was incubated at 55uC for 1 h
followed by a 5 min incubation at 95uC. Residual tissue were
removed by centrifugation at 16 000 x g for 2 min. This DNA was
used in a PCR reaction with the following primers: DTR1, 59-
GCCACCATGAAGCTGCTGCCG-39; DTR2, 59-TCAGTGG-
GAATTAGTCATGCC-39. Gene amplification was performed
using reagents from Applied Biosystems (Carlsbad, CA) in a 25 ml
PCR reaction mixture containing 2.5 ml 10x PCR buffer, 4 mM
MgCl2, 0.2 mM dNTPs, 0.4 mM each of primers and 0.06 U/ml
AmpliTaq DNA polymerase (4 min, 94uC; 15 s, 95uC; 1 min
63.1uC; 15 s 72uC, repeat previous steps for 35 cycles; 5 min
72uC). PCR products was electrophoresed on a 1.5 % agarose gel
in 1x Tris-acetate-ethylenediaminetetraacetic acid (TAE) buffer at
100 V. The transgenic diphtheria receptor (DTR) gives a 625 bp
band. For depletion of CD11c
+ cells in vivo, CD11c-DTR mice
were injected i.p. with 100 ng diphtheria toxin (Sigma-Aldrich) in
200 ml PBS. Mice were matched for age and sex within each
experiment and were at least 6 weeks old.
Antigens
OVA (ovalbumin) and TNP (picrylsulfonic acid/hydrate) were
obtained from Sigma-Aldrich (St Louis, MO). TNP was coupled to
OVA in 0.28 M cacodylate buffer, pH 6.9 as described [37]. The
coupling reaction was performed at room temperature for 90 min
and stopped by addition of an excess of glycyl-glycine (1 mg/ml,
Merck, Darmstadt, Germany). Free TNP was removed by
dialyzing against PBS. The number of TNP residues/OVA was
determined [37] and batches with a TNP to OVA ratio between 1
and 2 were used with similar results.
Antibodies
Monoclonal murine IgE-anti-TNP was derived from the B cell
hybridoma IGELb4 [38] and purified and stored as described
[16]. For flow cytometry we used PE-labeled anti-CD4 mAbs
(GK1.5), APC-labeled anti-CD11c (HL3), PE-labeled MHC-II I-
A
d (AMS-32.1), FITC-labeled anti-CD19 (1D3) and PE-labeled
anti-B220 (RA3-6B2), all from BD Biosciences (San Jose, CA). The
DO11.10 transgenic T cells were detected with FITC-labeled KJ1-
26 mAb (Caltag Laboratories, Burlingame, CA) specific for this
particular TCR heterodimer [39]. For confocal microscopy,
FITC-labled anti-B220 (RA3-6B2), biotinylated KJ1-26, and
APC-labeled streptavidin were used (all from eBioscience, San
Diego, CA).
Immunizations
Mice were immunized with purified IGELb4 (IgE-anti-TNP)
[38] and OVA-TNP in the tail veins in a total volume of 200 ml
PBS. IgE and antigen were pre-mixed in a test tube at room
temperature and injected within 1 h. Amounts of IgE and antigen
are detailed in the figure legends.
Flow cytometry
Single cell suspensions from spleens were treated with ACK
lysing buffer (0.15 M NH4CL, 1.0 M KHCO3, 0.1 mM
Na2EDTA, pH 7.3) for 3 min to remove erythrocytes, washed in
PBS and resuspended in FACS buffer (PBS with 2% fetal bovine
serum). 5610
5 cells were stained at 4uC for 30 min in 100 ml
FACS buffer with predetermined optimal amounts of labeled
antibodies. Cells with the forward- and side-scatter properties of
lymphocytes (for analysis of DO11.10 T cells) or all live cells (for
analysis of CD11c
+ cells) were collected on a FACScan cytometer
or a LSR II cytometer (both from BD Biosciences) and analyzed
using the FLOWJo Software. 223610
5 events were analysed.
OVA-specific DO11.10 T cells were identified as CD4
+KJ126
+
and dendritic cells as CD11c
+MHC-II
hi.
Isolation of cells
The MACS system (Miltenyi Biotech, Bergisch Gladbach,
Germany) was used to obtain cell suspensions depleted of, or
enriched for, defined populations. Single cell suspensions from
spleens were treated with ACK as described above, resuspended in
MACS buffer (PBS containing 0.5% bovine serum albumin and
2 mM EDTA) and labeled with anti-CD4-conjugated magnetic
IgE Enhances CD4 T Cell Responses via CD11c
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+ cells were collected using LS columns according
to the manufacturer’s instructions. The isolated cell population
was .96% CD4
+ as determined by flow cytometry. Spleen cells
were depleted of CD11c
+ cells by mixing with anti-CD11c-
conjugated magnetic beads followed by passage over an LD
column (which is specialized for depletion of cells): more than 94%
of CD11c
+MHC-II
hi cells were depleted (CD11c
2 population in
Figure 1A). To enrich for CD11c
+ cells (Figure 1B) spleen cells
were mixed with anti-CD11c-conjugated magnetic beads and
passed over an LS column (which is specialized for enrichment of
cells). Cells eluted from the column were .68% CD11c
+.T o
deplete for B cells (Figure 1A), spleen cells were mixed with anti-
CD19-conjugated magnetic beads followed by passage over an LD
column. The flow through cells were .98% CD19
2. To enrich
for B cells, the fact that all leukocytes except mature and immature
resting B cells express CD43 was used: spleen cells were mixed
with anti-CD43-conjugated magnetic beads, passed over an LD
column and the CD43
2 flow through cells (.98% CD19
+) were
used as B cells in transfer experiments.
Adoptive transfers
2.325.0610
6 CD4
+ cells from DO11.10 spleens (positively
selected as described above) and when applicable 17610
6 CD43
2
B cells from BALB/c or C57BL/6 (negatively selected as described
above) were adoptively transferred i.v. in 200 ml PBS.
3H-thymidin incorporation assay
BALB/c or CD23
-/- mice were immunized i.v. with 100 mgo f
OVA-TNP in PBS with or without 250 mg of IgE anti-TNP.
Controls were left unimmunized. After 4 hours, spleens from
BALB/c mice were removed and spleen cells were divided into
three fractions: one was left unfractionated, one was depleted of
CD19
+ cells and one was depleted of CD11c
+ cells whereas
CD23
-/- spleen cells were left unfractionated (Figure 1A). In
Figure 1B, CD11c
+ cells were enriched on LS columns (see above).
Unfractionated spleen cells were used as APC at a concentration
of 6610
5 cells/well. When fractionated APC populations were
used (Figures 1A & B), they were adjusted to the same volume as
before fractionation to contain the same numbers of the respective
APC as did unfractionated spleen cells. In Figure 1B, we also used
2x, 5x and 10x the number of APC as in the unfractionated
populations. APC were added in 100 ml f-DMEM (National
Veterinary Institute, Uppsala, Sweden) supplemented with
100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-gluta-
mine, 50 mM b-mercaptoethanol, and 5% heat-inactivated fetal
bovine serum (all from Sigma-Aldrich) to 96 well tissue culture
plates (Sarstedt, Nu ¨mbrecht, Germany) and irradiated (10 Gy).
1610
5 CD4
+ DO11.10 responder cells in 100 ml f-DMEM were
added to each well. After 48 h the cells were pulsed with 1 mCi
3H-thymidine (American Radiolabeled Chemicals, St Louis, MO)
for 18–24 h. Incorporation of
3H-thymidine was measured in a
beta counter (Wallac 1450 MicroBeta Trilux, Perkin Elmer,
Waltham, MA). Mean and SEM were calculated from five
replicate wells.
Confocal microscopy
Tissue sections were prepared as described previously [15].
Briefly, spleens were frozen and embedded in O.C.T. compound
(Sakura Finetek, Alphen aan den Rijn, The Netherlands) and
7 mm sections were cut using a cryostat. Air-dried sections were
collected onto glass microscope slides (Mentzel-Gla ¨ser, Braunsch-
weig, Germany) and stored frozen at 270uC. The slides were fixed
in ice cold 50% acetone for 30 s and then in 100% acetone for
5 min. Rehydration of the sections was performed in PBS for
15 min at room temperature. Sections were then blocked with 5%
horse serum (Sigma-Aldrich) in PBS for 1 h. After pouring off
blocking solution, 2 mg/ml FITC-labeled anti-B220 and 1 mg/ml
biotinylated KJ1-26, diluted in 100 ml blocking solution, was added
to each section and left for 1 h at room temperature. After washing
twice in PBSfor 5 min, 100 mlo f2mg/ml APC-labeled streptavidin
was added, sections were stained for 1 h and washed twice in PBS.
Slides were mounted in Fluoromount G (Southern Biotech,
Birmingham, AL) and immunofluorescence was detected by a
LSM 700 confocal microscope from Carl Zeiss (Thornwood, NY).
Photos of every T cell zone on four non-consecutive sections from
eachindividualspleenweretakenbyZen2009software(CarlZeiss).
Numbers of KJ1-26
+ T cells in each T cell zone were automatically
quantified using ImageJ software (NIH, Bethesda, MD).
Statistical analysis
Statistical differences between groups were determined by
Student’s t-test. Values for p.0.05 (not significant, ns), p,0.05
(*), p,0.01 (**) or p,0.001 (***) are indicated in the figures.
Results
CD11c
+ cells present IgE-antigen to CD4
+ T cells ex vivo
To investigate whether B cells (CD19
+)o rC D 1 1 c
+ cells
present IgE-antigen complexes in vivo, mice were immunized
with OVA-TNP alone or together with IgE-anti-TNP. Four
hours later their spleens were removed, cell suspensions
prepared, irradiated and used as APC (antigen presenting cells)
ex vivo. Spleen cells removed after 1, 2, 3, and 4 h could induce
efficient antigen presentation, with the best effect seen with APC
removed after 4 h (data not shown). Spleen cells removed after
13 h had lost their capacity to present antigen ex vivo (data not
shown). No additional antigen or immune complexes were
added to the cell cultures, ascertaining that only OVA-peptides
acquired in vivo w e r ep r e s e n t e do nM H C - I Io nt h ev a r i o u sA P C
populations. As responder cells, CD4
+ T cells from DO11.10
mice were used. These T cells have a transgenic TCR
recognizing OVA323–339 together with MHC class II I-A
d
[35]. Unfractionated spleen cells from mice immunized with
IgE-antigen complexes induced much more efficient T cell
proliferation than spleen cells from mice given OVA-TNP alone
whereas spleen cells from CD23
-/- mice could not induce T cell
proliferation (Figure 1A). Interestingly, spleen cells depleted of B
cells (CD19
2) were equally efficient as unfractionated spleen
cells, whereas spleen cells depleted of CD11c
+ cells (CD11c
2)
completely lost their antigen presenting capacity, although B
cells were present in this population (Figure 1A). In the
reciprocal approach, enriching spleen cells for CD11c
+ cells,
we found that CD11c
+ cells retained the antigen presenting
capacity of unfractionated spleen cells (Figure 1B). Upon
increasing the number of CD11
+ cells up to 10-fold of the
number present amongst the unfractionated spleen cells, also
the T cell proliferation increased dramatically (Figure 1B). As an
alternative approach, CD11c-DTR mice, expressing the high
affinity receptor for diphtheria toxin under the CD11c
promoter, were used as a source of APC in the ex vivo antigen
presenting assay. CD11c-DTR mice can be conditionally
depleted of cells expressing high amounts of CD11c by
treatment with diphtheria toxin [36] (Figure 2). Toxin-treated
and untreated CD11c-DTR mice were immunized with OVA-
TNP alone or in complex with IgE anti-TNP. Four hours later
their spleens were removed, spleen cells prepared, irradiated
and used as APC in the T cell proliferation assay as described
above. When total spleen cells from untreated CD11c-DTR
IgE Enhances CD4 T Cell Responses via CD11c
+ Cells
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they induced efficient T cell proliferation (Figure 1C). In
contrast, APC derived from the spleens of toxin-treated CD11c-
DTR mice were unable to induce T cell proliferation
(Figure 1C). Taken together, these observations suggest that
CD11c
+ cells, but not B cells, in mice immunized with IgE-
OVA complexes present antigen efficiently enough to induce
proliferation of specific CD4
+ T cells ex vivo.
IgE-mediated enhancement of T cell proliferation in vivo
depends on CD11c
+ cells
The conclusion from Figure 1 was deduced from an ex vivo
antigen presentation assay. Next, we analyzed the ability of IgE-
antigen complexes to induce T-cell proliferation directly in vivo in
mice lacking CD11c
+ cells. CD11c-DTR mice, and in some cases
littermate controls, were treated with diphtheria toxin leading to
depletion of 97% of CD11c
+ spleen cells in the CD11c-DTR mice
Figure 1. CD11c
+ cells present IgE-antigen to CD4
+ T cells ex vivo. A & B) BALB/c or CD23
-/- mice were immunized with 100 mg OVA-TNP alone
or together with 250 mg of IgE anti-TNP. After 4 h, spleens were removed, fractionated, and tested for ability to activate CD4
+ OVA-specific DO11.10 T
cells ex vivo. C) CD11c-DTR mice were treated with 100 ng diphtheria toxin or left untreated. After 24 hours, the mice were immunized as in A and
4 hours later spleen cells were removed and tested for ability to activate DO11.10 T cells ex vivo. A) is representative of two identical and 4 similar
experiments, B) of three similar experiments and C) of 5 identical and 2 similar experiments.
doi:10.1371/journal.pone.0021760.g001
IgE Enhances CD4 T Cell Responses via CD11c
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cells and immunized. Three days later the number of splenic
OVA-specific CD4
+ T cells were analyzed, either in flow
cytometry (Figure 3A, B) or in confocal microscopy (Figure 3C,
D). IgE enhanced T cell proliferation in wildtype littermates
equally well whether the mice had been treated with diphtheria
toxin or not, showing that the toxin itself did not suppress T cell
responses (Figure 3B, bars 1–4). In untreated CD11c-DTR mice,
IgE also enhanced T cell proliferation (Figure 3B, bar 5 and 6). In
sharp contrast, the ability of IgE to enhance T cell responses was
completely abolished in CD11c-DTR mice that had been depleted
of CD11c
+ cells by toxin treatment (Figure 3B, bar 7 and 8).
Analysis by an alternative approach, counting specific T cells in
spleen sections, gave similar results (Figure 3 C,D). These data,
strengthen the ex vivo data (Figure 1), and show that IgE-mediated
enhancement of CD4
+ T cell responses in vivo requires the
presence of CD11c
+ cells.
MHC-II-incompatible B cells rescue IgE-mediated
enhancement of T cell-proliferation in CD23
-/- mice
IgE cannot enhance CD4
+ T cell or antibody responses in
CD23
-/- mice, but transfer of syngeneic wildtype B cells can rescue
these functions [16]. In addition, bone marrow derived cells (B
cells), but not stromal cells (FDC), from wildtype mice rescued the
ability of IgE to enhance antibody responses in CD23
-/- mice [11].
Both observations demonstrate the requirement for CD23
+ B cells
in this system. T cell responses are MHC restricted. Therefore,
should the effector function of CD23
+ B cells be to present IgE-
antigen to DO11.10 T cells, only MHC-II compatible B cells
would rescue CD23
-/- mice. However, should the effector function
merely be to transport IgE-antigen to the spleen, both MHC
compatible and incompatible wildtype B cells would rescue the
response. To investigate this, CD23
-/- mice on a BALB/c
background (MHC-II
d) were reconstituted with B cells from either
C57BL/6 (MHC-II
b) or BALB/c (MHC-II
d). Coming from
wildtype mice, these B cells were CD23
+. All animals had been
transferred with DO11.10 T cells on the previous day and were
immunized with OVA-TNP alone or in complex with IgE on the
day of the B cell transfer. OVA-specific T cell proliferation was
assessed by flow cytometry of spleen cell suspensions (data not
shown) or confocal microscopy of spleen sections (Figure 4). As
expected, T cells in BALB/c mice (bar 1 and 2) responded well to
IgE-antigen whereas T cells in CD23
-/- mice (bar 3 and 4) did not
respond. Also as expected [16], T cell proliferation in CD23
-/-
mice was rescued by transfer of MHC-II compatible B cells (bar 5
and 6). Interestingly, MHC-II incompatible B cells (bar 7 and 8)
were equally efficient in rescuing T cell proliferation as were
MHC-II compatible B cells. This observation strongly suggests
that the role of CD23
+ B cells in this system is to transport rather
than to present IgE-antigen complexes. There was a possibility
that B cells from MHC-II incompatible mice could induce
alloreactive responses by the OVA-specific T cells. However,
neither BALB/c nor C57BL/6 B cells, transferred to CD23
-/-
mice which were left unimmunized, were able to induce
proliferation of DO11.10 T cells (Figure 4, bar 9 and 10).
Discussion
The aim of the present study was to find out whether IgE-
mediated enhancement of CD4
+ T cell responses in vivo is caused
by increased uptake and presentation of IgE-antigen by CD23
+ B
cells or whether it is more likely that these cells merely transport
IgE-antigen to B cell follicles, where other cells take over and
present the antigen to T cells. In summary, we were unable to find
evidence for presentation of IgE-antigen complexes by CD23
+ B
cells in vivo. This is based on several experimental approaches.
Using ex vivo antigen presentation assays we found (i) that CD19
-,
but not CD11c
2 spleen cells, taken from wildtype mice 4 h after
immunization with IgE-antigen, could induce proliferation of
specific CD4
+ T cells (Figure 1A), (ii) that positively selected
CD11c
+ spleen cells could induce proliferation of specific CD4
+ T
Figure 2. Diphtheria toxin depletes CD11c-DTR mice of CD11c
+ cells. CD11c-DTR mice were treated with 100 ng diphtheria toxin or left
untreated. Twenty-four hours later total spleen cells were analyzed in flow cytometry and dendritic cells were defined as CD11c
+, MHC-II
hi cells. The
numbers show % of live cells in a representative experiment with 97% depletion of dendritic cells.
doi:10.1371/journal.pone.0021760.g002
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+ cells. CD11c-DTR mice, and in B) also wild
type littermates, were treated with 100 ng diphtheria toxin or left untreated. The same day, the mice were transferred i.v. with 2.323.0610
6 CD4
+
DO11.10 spleen cells. Twenty-four hours after diphtheria toxin treatment, mice were immunized i.v. with 20 mg OVA-TNP with or without 50 mg IgE
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toxin-treated CD11c-DTR mice (where CD11c
+ cells are
conditionally depleted) 4 h after immunization with IgE-antigen,
lost their ability to induce proliferation of specific CD4
+ T cells
(Figure 1C). In a second approach we demonstrated that IgE-
antigen did not induce T cell proliferation in vivo in diphtheria
toxin-treated CD11c-DTR mice (Figure 3). Finally, both MHC-II
compatible and MHC-II incompatible CD23
+ B cells could
rescue the specific T cell response to IgE-antigen complexes in
CD23
-/- mice (Figure 4). As mentioned in the introduction, we
have previously shown that IgE-complexed antigen can be found
on peripheral B cells 10 minutes after immunizaiton and in the
splenic B cell follicles (on the surface of follicular B cells) 30
minutes after immunization [15]. This finding demonstrated a
new way for antigen to enter the follicles, namely attached via
IgE to CD23
+ recirculating B cells. It also provided a new
possible explanation to why CD23
+ B cells are required for IgE-
mediated enhancement of antibody and CD4 T cell responses.
Supported by in vitro findings this effect had been believed to be
caused by B-cell mediated antigen presentation to T cells
following uptake of IgE-antigen via CD23 [21,22,23,24,25].
The current data are suggestive of a scenario where CD23
+ B
cells transport IgE-antigen to the spleen where the antigen is
captured and presented to CD4
+ T cells by CD11c
+ cells.
Although we do not directly demonstrate the delivery of antigen
from B cells to CD11c
+ cells, we find that this is the explanation
that best fits available data. In the CD11c-DTR mice, a gene that
encodes the human diphtheria toxin receptor fused to green
fluorescent protein (GFP) is inserted under the control of the
CD11c promoter [36]. The promoter was initially considered
specific for dendritic cells, but closer investigation has revealed
activity also in alveolar macrophages, splenic marginal zone and
metallophilic macrophages, a subset of activated T cells, NK cells
and plasmablasts (reviewed in [40]). Nevertheless, we find it likely
that the predominant cells presenting IgE-antigen to CD4
+ T
cells are dendritic cells. We cannot exclude involvement of splenic
macrophages but the other CD11c
+ cells are not antigen
presenting cells. Dendritic cells are efficient APC and are able
to trigger naı ¨ve T cells, a capacity not always found amongst B
cells [32,33,34]. This has indeed been one of the arguments
against the idea that B-cell mediated antigen presentation
explains IgE-mediated enhancement. Mouse dendritic cells have
not been found to express CD23. The observation that pure B
cells can rescue the response to IgE-antigen in CD23
-/- mice [16],
(Figure 4) corroborates this and shows that although CD11c
+ cells
are required, they do not act via CD23.
Figure 4. MHC-II incompatible B cells rescue IgE-mediated enhancement of T cell proliferation in CD23
-/- mice. Mice were transferred
with 5610
6 CD4
+ DO11.10 T cells. The next day, indicated mice were transfused with B cells (spleen cells depleted of CD43
+ cells on a MACS column;
98% CD19
+) and subsequently immunized with 20 mg OVA-TNP, with or without 50 mg IgE anti-TNP. Three days later spleens were removed and the
number of KJ1-26
+ T cells in non-consecutive sections of T cell zones were analyzed by confocal microscopy (2–4 mice/group; 4–16 T cell zones/
mouse; mean values 6 SEM). Representative of two identical and one similar experiment.
doi:10.1371/journal.pone.0021760.g004
anti-TNP. Three days later, spleens were analyzed for CD4
+ KJ1-26
+ T cells by flow cytometry (A, B) or for KJ1-26
+ cells in confocal microscopy (C, D). A)
Representative dot-plot of flow cytometry data; values represent % CD4
+KJ1-26
+ cells of gated lymphocytes. B) Mean values 6 SEM of % CD4
+KJ1-26
+
of CD4
+ cells analyzed in flow cytometry (3 mice/group) C) Mean values 6 SEM of KJ1-26
+ cells in non-consecutive sections of T cell zones analyzed
by confocal microscopy (3 mice/group; 3–12 T cell zones/mouse). D) Visualization of representative T cell zones from each group: KJ1-26
+ cells (red)
and B220
+ cells (blue). B) is representative of 4 experiments and C) of 1 experiment.
doi:10.1371/journal.pone.0021760.g003
IgE Enhances CD4 T Cell Responses via CD11c
+ Cells
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e21760We do not yet know how IgE-antigen is transferred from B cells
to CD11c
+ cells. Intercellular exchange of proteins can occur in
several different ways, e.g. via exosomes or trogocytosis [41]. Since
dendritic cells are present at the boundary between T and B cell
zones and also in B cell follicles [42], there should be ample
opportunity for delivery of the IgE-antigen complexes from B cells
to dendritic cells. The simplest explanation is that the presence of
IgE-antigen on the B cell surface triggers neighboring dendritic
cells to take up antigen via pinocytosis or endocytosis. Alterna-
tively, exosomes containing CD23 and IgE-antigen bound to it,
secreted by B cells after endocytosis of surface bound CD23 [43],
may be very palatable to nearby dendritic cells. Antibody-antigen-
complement complexes are transported on marginal zone B cells,
expressing high levels of complement receptor 1 and 2, from the
marginal zone to B cell follicles where they are delivered to FDC
[44,45]. Apart from B cells, FDC are the only cells in B cell follicles
that express CD23. However, FDC do not seem to be involved in
IgE-mediated enhancement, shown by the fact that B cells alone
rescue the response in CD23
-/- mice [16] (Figure 4) and that bone
marrow chimeras with CD23
- FDC respond well to IgE-antigen
[11]. Therefore, a similar role for FDC in capturing IgE-antigen
from follicular B cells as they have in capturing antigen-antibody-
complement from marginal zone B cells, is unlikely. Instead our
data suggest an alternative route for antigen handling where IgE-
antigen complexes are transported by peripheral CD23
+ B cells to
B cell follicles where they are delivered to dendritic cells. Although
we are not aware of any previous examples of antigen delivery
from B cells to dendritic cells, the reverse has been observed
[46,47].
Several laboratories, including our own, have demonstrated that
B cells via CD23 can take up and present IgE-antigen to T cells in
vitro [21,22,23,24,25]. Nevertheless, the data presented here
strongly argue against that B-cell-mediated antigen presentation
explains why IgE is such a potent enhancer of T cell responses in
vivo. The ex vivo assay (Figure 1) differs from previous in vitro studies
in that the APC are only able to interact with the antigen while
they are still in the animal - no further antigen is added to the
cultures. Allowing cells and IgE-antigen to incubate in vitro may
facilitate for CD23
+ B cells to take up the complexes, as compared
to the in vivo situation where the effective antigen concentration is
smaller and the B cells are mobile. In addition, antigen
transportation is not required in vitro and the ability of B cells to
endocytose IgE-antigen via CD23 therefore may become pre-
dominant. This is an additional example of discrepant results
obtained from in vivo and in vitro studies of the antibody feedback
regulation system. IgG-mediated suppression of erythrocyte
responses was independent of FccRIIB in vivo but not in vitro
[48,49] and complement-tagged antigen could be taken up via
complement receptors 1 and 2 on B cells and presented to T cells
in vitro [50,51,52] but not in vivo [53].
Apart from its role in IgE-mediated enhancement of immune
responses, CD23 is a negative regulator of IgE production. This is
evidenced by increased IgE levels in CD23 knockout mice [54]
and in mouse strains where CD23 is mutated [55,56] as well as by
reduced IgE production in transgenic mice overexpressing CD23
[57]. Interestingly, IgE-mediated enhancement works well in mice
overexpressing CD23, showing that the negative and positive
regulatory effects of CD23 are not mutually exclusive [25]. This is
also what would be expected if the negative effect is caused by
changes in B cell signaling whereas the positive effect is caused by
transportation only.
Another interesting function of CD23 is to mediate transepi-
thelial transport of IgE-antigen across intestinal barriers and across
respiratory epithelium [20,58,59]. This effect is dependent on the
CD23b isoform, whereas IgE-mediated enhancement of in vivo
antibody responses is dependent on CD23a [12]. Nevertheless, it is
an interesting parallel that IgE-antigen complexes can be
transported bound to CD23 both on enterocytes [58,59], airway
epithelial cells [20] and B cells [15].
CD23 is known as the low affinity receptor for IgE, but does in
fact have a dual affinity ranging from 227610
6 M
21 to
227610
7 M
21 [60]. The higher affinity is associated with the
oligomeric, membrane bound form of the receptor [60] and up to
80% of peripheral B cells have recently been shown to be
preloaded with IgE bound to CD23 [61,62]. Presumably this IgE
is sampled from the total IgE in the individual, thus reflecting the
antigen experience of the host, and would enable rapid capture
and transport of many different antigens by CD23
+ B cells. One
argument against a significant role of IgE in immune regulation
has been that the serum levels are exceedingly low. However, the
observations that B cells can be preloaded with IgE [61,62] suggest
that they may have acquired high enough concentrations of
relevant IgE to mediate e.g. antigen transport regardless of a low
serum concentration at the time of antigen entry. CD23 is a C-
type lectin, a family of receptors known to act as pattern
recognition receptors recognizing carbohydrate structures on
pathogens [63]. Therefore, CD23 most likely can bind directly
to certain carbohydrates expressed on pathogens. This may be an
additional, IgE-independent, way for CD23
+ B cells to transport
antigen.
In summary we have presented data supporting the idea that
peripheral CD23
+ B cells capture IgE-antigen and transport it to
splenic B cell follicles where antigen is delivered to dendritic cells
which subsequently present it to T cells. The data argue against a
role for CD23
+ B cells in presenting IgE-antigen to T cells in vivo.
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